DeuteRx has pioneered Deuterium-Enabled Chiral Switching (DECS) to stabilize and characterize the preferred enantiomers for the racemic active ingredients of >13 marketed drugs.
Chiral Switching – Since the 1990’s, many drugs have been ‘switched’ from a racemic mixture of two, stable mirror-image compounds (enantiomers) to the single, preferred enantiomer resulting in improved therapeutic properties such as improved efficacy or reduced side effects. Two successful and profitable ‘chiral switches’ include Prilosec® to Nexium® and Zopiclone® to Lunesta®.
Deuterium-Enabled Chiral Switching (DECS) – Numerous drugs are still being developed and marketed with racemic active ingredients because the enantiomers interconvert. Representative drugs include Actos®, Aricept®, Contrave®, and Revlimid®. Replacing the exchangable hydrogen at the chiral center with deuterium enables stabilization and characterization of the single, preferred enantiomer with new composition of matter patent protection and an expedited path to market. DRX-065, the deuterium-stabilized enantiomer of pioglitazone, is the lead program at DeuteRx being pursued for NASH and AMN.
with New IP &